Table 5.
Medication preference, medication adherence, and diet therapy adherence
| Week | Dapagliflozin group | DPP4i group | p value | ||||
|---|---|---|---|---|---|---|---|
| n | n (%) | n | n (%) | ||||
| Medication preference | 0 | Prefer SGLT2i | 119 | 22 (18.5) | 120 | 15 (12.5) | 0.007 |
| Prefer DPP4i | 6 (5.0) | 21 (17.5) | |||||
| Neither | 91 (76.5) | 84 (70.0) | |||||
| 24 | Prefer SGLT2i | 106 | 38 (35.8) | 117 | 10 (8.5) | < 0.001 | |
| Prefer DPP4i | 6 (5.7) | 33 (28.2) | |||||
| Neither | 62 (58.5) | 74 (63.2) | |||||
| Medication adherence | 24 | 122 | 91.9 ± 14.8 | 123 | 94.1 ± 9.6 | 0.16 | |
| Diet therapy adherence | 0 | 95 | 3.0 [3.0, 4.0] | 96 | 3.0 [3.0, 4.0] | 0.74 | |
| 24 | 95 | 3.0 [3.0, 4.0] | 106 | 3.0 [3.0, 4.0] | 0.56 | ||
Data are presented as frequency (percentage), mean ± standard deviation, and median [first quartile, third quartile] for medication preference, medication adherence, and diet therapy adherence, respectively. p values for intergroup comparisons were obtained by using chi-square test, two-sample t test, and Wilcoxon test for medication preference, medication adherence, and diet therapy adherence, respectively
DPP4i dipeptidyl peptidase inhibitor, SGLT2i sodium–glucose cotransporter 2 inhibitor